Catalog Number：VQ2675H
Human VCAM-1/CD106 VeriQuant Immunoassay Kit
Copy Product Infomation
Size：
96 T
Price：
Inquiry
Manual
MSDS
User Guide(a) Two monoclonal antibodies against distinct epitopes are conjugated with oligo probes, then form a sandwich complex with the antigen.
(b) Following antigen recognition by the paired antibodies, the conjugated oligonucleotides are spatially proximate, and generate an amplifiable dsDNA template under the enzymatic action.
(c) qPCR amplification is then performed. CT values correlate inversely with protein concentration, and sample target concentrations are calculated via standard curve.
Color-coded reagents components for easy identification
Kit outer packaging and components packaging
Product Operation Video
Product Details
| Product Name | Human VCAM-1/CD106 VeriQuant Immunoassay Kit | Species | Human |
| Gene Alias | VCAM1 | Gene ID | 7412 |
| Uniprot ID | P19320 | Protein Alias | Human VCAM-1/CD106 |
| Detection Method | Proximity-based Immunoassay | Sensitivity | 0.541pg/mL |
| Assay Instrument | qPCR Instruments | Detection Range | 6.4-100000 pg/mL |
| Sample Type | Serum, Plasma, Tissue homogenates, Cell lysates, Cell culture supernates and Other biological fluids；Sample Volume=1~5μL | ||
| Total Assay Time | 2 H | Manual Handling Time | 20 min |
| Shipping Temperature | Ultra-low temperature phase-change materials | Storage Temperature | -20°C |
| No Washing Step | Yes | Tag or Dye | FAM™ |
| Kit Info | N/A | ||
| Target Info | VCAM-1 is a single-pass type I membrane protein, contains 7 Ig-like C2-type domains. It is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes. | ||